No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma
the ONA take:
According to initial results presented this week at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, the use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma who are at a high risk of recurrence.
The phase 3 trial conducted by the ECOG-ACRIN Cancer Research Group is the first and largest study reporting on the efficacy of sunitinib or sorafenib in patients who have undergone surgery to remove the kidney tumor.
"Unfortunately we found that the use of sunitinib or sorafenib in this setting did not reduce the incidence of recurrence as compared to standard care," said lead researcher Naomi B. Haas, MD, from the University of Pennsylvania's Abramson Cancer Center in Philadelphia.
For the international, phase III study, researchers enrolled 1,943 patients considered at high risk for recurrence following surgery to remove a kidney tumor and randomly assigned them to receive sorafenib, sunitinib, or placebo for 1 year.
Results of the study showed a median progression-free survival of 5.6 years for those treated with sunitinib compared with 5.6 years for those treated with sorafenib and 5.7 years for those who received placebo.
Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|